Melanomas with low levels of MITF are resistant to MAPK inhibitors and tend to exhibit high levels of NF-κB and AXL, while melanoma with high MITF levels exhibit low NF-κB activity and are more sensitive to MAPK inhibition [37,122,139]. This evidence concerns the gene NFKB1 and melanoma.